Home›Compare›Emerge Weight Loss vs MadeMed

Emerge Weight Loss vs MadeMed: Which Is Better?

Head-to-head comparison of Emerge Weight Loss and MadeMed based on our independent scoring across trust, value, experience, product range, and reputation — plus real pricing for the treatments they both offer.

Our Verdict

Emerge Weight Loss scores higher overall in our independent evaluation (68.6/100 vs 57.3/100), leading on trust & safety, value, experience, reputation. MadeMed comes out ahead on product range. MadeMed has the lower entry price (from $30/mo vs $224/mo), so the better value depends on which treatment you need.

Emerge Weight Loss is a small, Miami-area telehealth brand offering a single flat-rate, tirzepatide-only compounded GLP-1 program with named compounding-pharmacy partners.

Visit Emerge Weight Loss
57

MadeMed is a Houston-registered telehealth brand selling compounded injectable and oral GLP-1s, sermorelin, NAD+ and tadalafil through the Xpedicare provider network.

Visit MadeMed

Score Breakdown

DimensionEmerge Weight LossMadeMed
Overall Score68.6/100 ✓57.3/100
Trust & Safety30%74/100 ✓55/100
Value25%76/100 ✓66/100
Experience20%78/100 ✓45/100
Product Range15%42/10072/100 ✓
Reputation10%55/100 ✓45/100

At a Glance

Founded——
HeadquartersMiami, FLHouston, TX
Publicly tradedNoNo
Treatment categories13
Treatments listed17
Starting price$224/mo$30/mo

Pricing Where They Compete

Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.

CategoryEmerge Weight LossMadeMed
Weight Loss / GLP-1$224
Compounded Tirzepatide Auto-Pilot Plan
$99–$199
Compounded Semaglutide (injectable)

Emerge Weight Loss

+Names its compounding pharmacy partners (Hallandale and Empower Pharmacy), a transparency practice not all compounded-GLP-1 competitors follow
+Flat, all-in '$224/4 weeks, no hidden fees' pricing displayed publicly, with HSA/FSA accepted
+High Trustpilot rating (4.7/5) with specific praise for responsive, text-based support and reported weight-loss outcomes
−Tirzepatide-only — does not offer semaglutide, so patients who don't tolerate or prefer tirzepatide have no in-house alternative
−Small Trustpilot sample size (198 reviews) relative to competitors, so its rating is less statistically reliable
−Founding year and states served are not disclosed on the website, limiting how much operating history can be verified
Read the full Emerge Weight Loss review →

MadeMed

+Offers both injectable and oral/sublingual versions of semaglutide, tirzepatide and sermorelin, plus NAD+ as injection or nasal spray
+Operating entity, provider network (Xpedicare) and a partner pharmacy (Red Rock) are named in the terms and About page
+Advertised GLP-1 entry pricing from $99/mo is at the low end of the market
−Product pages showed no pricing or product detail during our research, in a direct fetch or a real browser
−Advertised prices and state coverage (about 40 states) come from brand-issued press releases and can't be verified on-site
−No Trustpilot or other independent patient reviews; public coverage is mostly paid newswire content
Read the full MadeMed review →

Emerge Weight Loss vs MadeMed — FAQ

Is Emerge Weight Loss better than MadeMed?

▾

Emerge Weight Loss scores higher overall in our independent evaluation (68.6/100 vs 57.3/100), leading on trust & safety, value, experience, reputation. MadeMed comes out ahead on product range. MadeMed has the lower entry price (from $30/mo vs $224/mo), so the better value depends on which treatment you need.

Is Emerge Weight Loss or MadeMed cheaper?

▾

MadeMed has the lower starting price (from $30/mo vs $224/mo for Emerge Weight Loss). Starting prices are for the cheapest treatment each offers — compare the specific treatment you need, and check what each price includes.

What do Emerge Weight Loss and MadeMed both offer?

▾

Both platforms treat Weight Loss / GLP-1. Emerge Weight Loss covers 1 treatment category total and MadeMed covers 3.

Still deciding?